Result of AGM

RNS Number : 9743M

Diaceutics PLC

26 May 2022

 

26 May 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Results of Annual General Meeting

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed by a show of hands.

The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website, www.diaceutics.com .

Resolution		For (excluding at Chair's discretion)		Against		Total votes cast	Withheld
		Number of votes	%	Number of votes	%		Number of votes
1	Ordinary resolution to receive and consider the 2021 Financial Statements	62,700,675	100.00%	0	0.00%	62,700,675	Nil
2	Ordinary resolution to approve the directors' remuneration report	62,693,325	99.99%	7,350	0.01%	62,700,675	Nil
3	Ordinary resolution to re-elect Nick Roberts as a director	62,700,675	100.00%	0	0.00%	62,700,675	Nil
4	Ordinary resolution to re-elect Charles Hindson as a director	61,651,904	98.32%	900,000	1.44%	62,551,904	Nil
5	Ordinary resolution to re-appoint  PricewaterhouseCoopers LLP as auditors	62,550,243	99.75%	1,661	0.01%	62,551,904	Nil
6	Ordinary resolution to authorise the directors to determine the remuneration of the auditors	62,700,675	100.00%	0	0.00%	62,700,675	Nil
7	Ordinary resolution to authorise the directors to allot shares	62,699,175	100.00%	0	0.00%	62,700,675	1,500
8	Special resolution to authorise the directors to disapply pre-emption rights	62,697,164	99.9%	2,011	0.01%	62,699,175	1,500
9	Special resolution to authorise the directors to purchase own shares	60,606,084	99.99%	8,661	0.01%	62,614,745	2,085,930

Enquiries:

Diaceutics PLC
Peter Keeling, Chief Executive Officer	Via Alma PR
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: [phone]
Ben Maddison, Stewart Wallace, Nick Adams
Alma PR	Tel: [phone]
Caroline Forde, Kieran Breheny, Matthew Young	[e-mail]

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

END

 

 

RAGKZGZKFVKGZZM